

AmpliPhi Biosciences to Hold 2017 Second Quarter and Business Update Conference Call on August 14

SAN DIEGO--([BUSINESS WIRE](#))--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-based technology, announces that management will hold a business update conference call on Monday, August 14, 2017 beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

Live Call:	U.S.	877-866-5534
	International	346-406-0930
	Passcode	53278337

Live
Webcast: [AmpliPhi IR Website](#)

The webcast replay will be available approximately 2 hours after completion of the call and will be archived for 30 days.

Replay:	U.S.	855-859-2056
	International	404-537-3406
	Passcode	53278337

The replay will be available for 48 hours starting approximately 2 hours after completion of the call

About AmpliPhi Biosciences

AmpliPhi Biosciences Corporation is a biotechnology company pioneering the development and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. In May 2017, AmpliPhi announced a new strategic emphasis on developing precisely targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. AmpliPhi has reported results from two Phase 1 clinical trials of AB-SA01, one for the treatment of *Staphylococcus aureus* in chronic rhinosinusitis patients (safety and preliminary efficacy) and one to evaluate the safety of AB-SA01 when administered topically to the intact skin of healthy adults. AmpliPhi has additional bacteriophage-based preclinical products in development, including for the treatment of *Pseudomonas aeruginosa* infections. AmpliPhi has received positive feedback from the U.S. Food and Drug Administration (FDA) and UK Medicines and Healthcare products Regulatory Agency (MHRA) on its development plans.

CONTACT:

At the Company:
AmpliPhi Biosciences
Matthew Dansey
(858) 800-4869
md@ampliphio.com

or
Investor Relations:
LHA Investor Relations
Jody Cain
(310) 691-7100
jcain@lhai.com

<https://investor.armatapharma.com/2017-08-07-AmpliPhi-Biosciences-to-Hold-2017-Second-Quarter-and-Business-Update-Conference-Call-on-August-14>